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Background: According to the literature, parenteral testosterone replacement therapy (TRT)-induced polycythaemia is
associated with cardiovascular events. No or minimal data exist for the prevalence of TRT-induced polycythaemia in late-
onset hypogonadism (LOH) patients from South Africa. Polycythaemia is the side effect most frequently associated with
parental TRT formulations.
Design: This was a quantitative, observational, descriptive, retrospective study.
Setting: The study setting was a private practice male clinic in Emalahleni.
Subject: An all-inclusive sampling method was used.
Outcome measures: The main outcome measure for polycythaemia was haematocrit (Hct). An Hct percentage of > 50% at
month 3 (post-treatment initiation) constituted a positive diagnosis for polycythaemia. For the rise in total testosterone (TT)
and Hct, the variance was used as documented between pre- and post-treatment initiation.
Results: The prevalence of polycythaemia was 34%. A statistically significant increase in both TT and Hct was observed. The
Cohen’s d effect size was 0.68 and 0.73, respectively, for TT and Hct.
Conclusion: Depot-testosterone undecanoate parenteral formulation induces polycythaemia in LOH patients, where the rise in
TT demonstrates the effectiveness of therapy.
Keywords: depot-testosterone haematocrit, late-onset hypogonadism, polycythaemia, testosterone replacement therapy,
undecanoate
Introduction
Hypogonadism is a syndrome related to androgen deficiency.
This can be sub-classified into four separate syndromes to
narrow down the specific aetiology: primary hypogonadism,
secondary hypogonadism, androgen insensitivity/resistance
hypogonadism and late-onset hypogonadism (LOH). The
inability of the testes to produce androgens even if they
are sufficiently stimulated is known as primary hypogonad-
ism. A disruption of the neuroendocrine system results in sec-
ondary hypogonadism and androgen insensitivity/resistance
hypogonadism is due to the inability of the androgens to
elicit a full response on the androgen receptor. LOH is
defined as the disruption of stimulus between the neuro-
endocrine system and the testes that under normal circum-
stances will lead to androgen production and secretion by
the testes. LOH men had normal development through
puberty and therefore developed accordingly in sexual
characteristics.1
The ageing population is expected to increase,2 yet ageing does
not always parallel optimum health. Low levels of total testoster-
one (TT) in association with sexual symptoms that comprise low
libido, erectile dysfunction and a poor morning erection are the
clinical and biochemical symptoms that manifest the most in
patients prior to a positive LOH diagnosis.3,4 These symptoms
are not only the first clinical symptoms to manifest but, accord-
ing to Liu et al., may be used in combination with low levels of
testosterone to diagnose LOH.5
TRT is the cornerstone of treatment for LOH and other androgen
deficiency syndromes.6 Benefits of treatment include a rise in
the TT level, where a TT level above 12 nmol/l is considered
physiologically normal.2 Additional clinically beneficial effects
related to TRT include the increase of bone mineral density,
and favourable effects on muscle mass, sexual parameters,
strength and mood.2,7 Another secondary advantage associated
with TRT is the improvement of the inverse relationship between
low testosterone levels and metabolic syndrome, which includes
clinical conditions such as central obesity, hypertension and
unsatisfactory lipid profiles that are associated with a greater
risk for cardiovascular disease and atherosclerosis.2 Furthermore
TRT significantly improves glycaemic control of the type 2 dia-
betes mellitus patient and it is recommended that all these
male patients are also screened for hypogonadism.4 In order
to maximise patient adherence and cooperation, different for-
mulations exist that should be prescribed in accordance with
patient blood levels and ability to comply with dose frequency
and route.8
Various types of TRTs are available, which include oral formu-
lations, implantable pellets, parenteral formulations, buccal
tablets, transdermal patches and topical gels.9 Side effects
most frequently associated with TRT formulations are: less
than optimal taste for oral tablets, person-to-person transfer
due to close contact of individuals shortly after application of
the topical gels, and gum pain is frequently reported with the
use of buccal tablets.8 Furthermore, transdermal patches cause
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skin rash in some patients, where extrusion of the implantable
pellet has also been documented in a number of treated
patients.10 Side effects most frequently experienced related to
the parenteral dosage formulations such as testosterone cypio-
nate, testosterone propionate or testosterone enanthate are
supra-physiological testosterone levels shortly after the dose,
followed by sub-therapeutic levels prior to the next dose.9,11
This phenomenon can partly be explained by molecular esterifi-
cation. Esterification processes make molecules more lipid
soluble, which, in turn, enables the molecule to be more
readily released from circulation.12 This might benefit the mol-
ecules’ pharmacokinetic profile, as in the case of the depot-tes-
tosterone undecanoate formulation.11 The pharmacokinetic
benefits of the depot-testosterone undecanoate formulation
include a more favourable spread of TT levels around the
median physiological testosterone value, with a beneficial clini-
cal implication of less frequent dosing than older generations of
testosterone. However, an increase in the number of erythro-
cytes above the physiological normal levels, also known as ery-
throcytosis or polycythaemia, is the risk most frequently
encountered with parenteral TRT,13 even though the exact
mechanism of action still needs to be explained.14 Androgen
replacement therapy induced polycythaemia originates via the
bone marrow haematopoiesis pathway, as an alternative to
the oxygen-erythropoietin cascade.15
Despite polycythaemia-induced cardiovascular complications,
the depot-testosterone undecanoate parenteral formulation
remains the only registered TRT in South Africa to treat
LOH.16,17 Subsequently, this study has set out to evaluate, in ret-
rospect, the prevalence of polycythaemia among diagnosed
LOH patients who have received depot-testosterone undecano-
ate TRT and the possible clinical significance thereof.
Method
Setting
The study took place in a private practice located in Mpuma-
langa, ranging from Emalahleni (formerly known as Witbank),
Groblersdal and Nelspruit, South Africa. By undertaking a
study that covered all these towns, a large study population
from different geographical areas was ensured. The study was




Data were subject to the following criteria. Only data of con-
firmed LOH cases were included in the current study, where
depot-testosterone undecanoate was initiated as normal stan-
dard practice according to the specialist prescription.
Exclusion criteria
Data of patients with signs and symptoms of conditions such as
severe sleep apnoea, male breast cancer or an Hct > 50% at the
time of diagnosis, and prostate specific antigen >4 ng/ml at the
time of diagnosis were excluded from the study, as alternative
treatment plans had to be applied by the treating practitioner.
Research procedure
This study investigated retrospective data of diagnosed LOH
men who followed the European Association of Urology treat-
ment regimen for depot-testosterone undecanoate for at least
a three-month period. The observation was done in retrospect,
where treatment was initiated on day 1, a booster at six weeks
after the first injection, and then after 12 weeks.1,9
The data required to execute the study were obtained from the
clinical data manager of the specified private practice. These
included re-identified patient data of laboratory TT levels and
Hct values as recorded by the clinical data capturer at the
time of diagnosis (month 0), and three months post-treatment.
A positive diagnosis for polycythaemia was made once an Hct
percentage of > 50% was obtained from the laboratory. The
raw data were sent to Statistical Consultation Services of
North-West University for data analyses.
Data analysis
The Statistical Analysis System®, SAS 9.3® (SAS Institute Inc., Cary,
NC, USA) was used to analyse the data. Categorical variables
were reported as frequencies and percentages. Continuous vari-
ables were reported as mean ± SD (normally distributed data) or
median (25th, 75th) percentiles (skewed data). Histograms and
Q-Q plots were used to evaluate the distributions. Possible out-
lying values were identified by means of box-and-whiskers plots,
with z-score values larger than the absolute value of three.
The dependent t-test was used to compare the change
between the two time points. Cohen’s d-value was used to
determine the practical significance of the results (with d≥ 0.8
defined as a large effect with practical significance).
Results
The cohort of LOH patients was observed retrospectively for a
three-month study period. Polycythaemia was observed in
34% of participants.
The mean Hct rose from 45.62% (standard deviation [SD] 4.79) to
49.11% (SD 3.98). The change in mean Hct over the study period
was 3.49% (SD 4.46). The rise in Hct was statistically significant,
p-value < 0.001. The effect size was 0.73, suggestive of a large
impact.
At the beginning of the study, the participants’ mean TT was
8.18 nmol/l (SD 3.71), and at the end of the three-month
period it was 12.39 nmol/l (SD 6.18). The mean increase of TT
over the study period was 4.21 nmol/l (SD 6.47). The increase
in TT had a statistically significant p-value < 0.001. Cohen’s
d-value of 0.68 suggests a large practically significant change
over the two time points. A negative association between Hct
and TT was noted after the study period.
Discussion
Depot-testosterone undecanoate-induced polycythaemia
occurred in 34% of study participants, with an overall study
period recorded mean Hct of 49%. This mean Hct value was
below the upper level stated as pathognomonic for polycythae-
mia (Hct > 50%).1 The rise in TT of the study participants (n = 49)
after initiated treatment proved to be practically significant, as
TT levels increased to within the normal physiological TT level
of 12 nmol/l.2 The observed change in Hct and TT values was
statistically and practically noteworthy, indicative of the impor-
tance to evaluate benefits and risks related to patient care.
Polycythaemia—the increase of erythrocytes leading to higher
levels of blood viscosity—is a known risk when a patient
receives TRT.1,2 Furthermore, it is well documented that poly-
cythaemia is a dose-dependent side effect of TRT and that
both dose and delivery system affect the magnitude of the
Hct increase.3,14,15,18 As observed in this study, a higher
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after initiated treatment proved to be practically significant, as
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tance to evaluate benefits and risks related to patient care.
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polycythaemia prevalence is noted in some study participants,
as opposed to no cases of polycythaemia recorded in studies
done by Conaglen et al. and Yassin and Haffejee.9,11 A possible
reason for the difference noted in polycythaemia prevalence
between studies is the studied population of hypogonadal
men. Some authors reported Hct values that consisted of men
who had previous encounters with TRT, where others used a
mixed-patient population that comprised men with primary,
secondary and late-onset hypogonadism.8,19 This study,
however, used only treatment-naive LOH patients. Furthermore,
over- or under-reporting of polycythaemia might occur due to
mean Hct values and standard deviations that mask individual
results that are over the upper Hct limit. The individual
masking effect was explained by Haider et al., where the mean
Hct of 122 LOH male patients at month 3 of initiated therapy
revealed no cases of polycythaemia in relation to a 5% preva-
lence of polycythaemia after evaluating patients individually
post-treatment (at month 3).20 The latter might be resolved by
grouping patients according to their own individualised Hct
values.20 Finally, a polycythaemia-induced Hct cut-off value
still eludes prescribers and patients as discussions still exist as
to what the peak cut-off Hct percentage should be. Haematocrit
values ranging from 50% to 54% were chosen by most
authors.1,14 This study used an Hct percentage of > 50% as
pathognomonic for polycythaemia, which is in line with the
European Association of Urology guidelines.1
It is important to be aware of the possible mean increase in Hct,
as a steep rise above the Hct threshold level may lead to adverse
effects such as strokes, myocardial infarctions or deep vein
thrombosis that might well lead to a pulmonary embolism.20,21
Despite TRT-induced erythropoiesis leading to polycythaemia,
randomised control studies still cannot demonstrate the direct
relationship between TRT-induced erythrocytosis and cardiovas-
cular events.22 In a recent review published by Hackett,7 TRT
patients presented with a 6% increase in risk for polycythaemia.
However, mortality rates were lower in the TRT cohort of
patients than for treatment-deprived patients, which demon-
strates the beneficial effect of TRT for hypogonadism patients.
There is a relationship between the mean change in Hct
values of this study and other studies, which demonstrates the
similarities of a mean change in Hct values between inter-
national patients and South African patients.18 This is note-
worthy for the South African population, as TRT-induced
polycythaemia studies are not well defined in South Africa. Sub-
sequently, Assi and Baz noted that any man presenting with an
Hct > 52% can be diagnosed with polycythaemia23—further
strengthening evidence that the South African male population
might be comparable with international cohorts.
The statistically significant increase in testosterone experienced
by the current cohort of subjects leads to TT levels close to or
within normal physiological TT ranges, consistent with inter-
national guidelines.1 The rise in TT levels depends on the base-
line TT value.
Observed study limitations were the lack of hematopoietic sup-
plementation history of patients and the fact that patients were
not stratified according to possible underlying co-morbid con-
ditions, e.g. diabetes, obesity, HIV and anaemia, as these are
knownconditions that have a variable effect on testosterone levels.
Conclusion
The prevalence of polycythaemia for the South African cohort of
studied men was higher than that of their international
counterparts. However, the mean increase of Hct was below
the pathognomonic cut-off used to diagnose polycythaemia.
The conclusion can therefore be made that polycythaemia is a
statistically significant occurrence for some individuals, but,
when put into perspective related to the broader community,
polycythaemia is an isolated occurrence that should be screened
for during the first few weeks to months after treatment
initiation. Therefore, prescribers should strongly recommend
screening for polycythaemia as per published guidelines. The
rise in TT levels was sufficient to conclude that less than
optimal baseline TT levels will rise to within normal physiological
TT levels. To conclude, despite a greater statistically significant
risk for attaining TRT-induced polycythaemia, further research
needs to be conducted to determine the practical significance
thereof.
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